GlassScriptPhysician profile
Magon Lord
NPI 1710550843
$3,494.97
in general payments reported to CMS, 2019-2025
25 companies · $1,321 in 2025
The $1,321 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $237 · 2022: $16.00 · 2023: $634 · 2024: $1,287 · 2025: $1,321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,242.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,114.61 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $659.22 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $524.99 | 2023-2025 | Tremfya, Stelara, Simponi |
| Qol Medical, LLC | $164.10 | 2023-2025 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $142.61 | 2025 | Iqirvo |
| Pfizer INC. | $136.28 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $109.49 | 2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $109.37 | 2021 | |
| Genzyme Corporation | $93.36 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.28 | 2023-2025 | Entyvio |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.41 | 2021 | |
| Gilead Sciences, INC. | $41.80 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $33.78 | 2021-2022 | |
| Celgene Corporation | $31.67 | 2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $30.90 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $30.14 | 2024-2025 | Zenpep |
| Mallinckrodt Hospital Products INC. | $27.34 | 2025 | Terlivaz |
| Madrigal Pharmaceuticals | $23.99 | 2025 | Rezdiffra |
| Genentech USA, INC. | $19.82 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $17.88 | 2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.66 | 2021 | |
| Nestle Healthcare Nutrition INC. | $16.29 | 2023 | |
| Celltrion USA INC. | $15.87 | 2025 | Vegzelma |
| Amgen INC. | $15.21 | 2023 | Amjevita, Avsola |
| Bayer Healthcare Pharmaceuticals INC. | $12.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Magon Lord listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.